Xavier-Santos Douglas, Padilha Marina, Fabiano Giovanna Alexandre, Vinderola Gabriel, Gomes Cruz Adriano, Sivieri Katia, Costa Antunes Adriane Elisabete
School of Applied Sciences (FCA), State University of Campinas, 1300 Pedro Zaccaria St, Zip Code 13484-350, Limeira, SP, Brazil.
Department of Social and Applied Nutrition, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Zip Code 21941-902, Brazil.
Trends Food Sci Technol. 2022 Feb;120:174-192. doi: 10.1016/j.tifs.2021.12.033. Epub 2022 Jan 2.
Coronavirus disease-19 (COVID-19) is an infectious disease transmitted by the virus responsible for the severe acute respiratory syndrome 2 (SARS-CoV-2), which exhibit several clinical manifestations including gastrointestinal symptoms.
This review aimed to provide insights and perspectives for the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention/treatment and/or modulation of the microbiota in COVID-19 patients. Eighty-four studies published in the Scopus database from the onset of the pandemic until December 2021 were assessed and submitted to a bibliometric analysis adapted from VOSviewer software.
Through bibliometric analysis, it might be suggested that the modulation of the gut/lung microbiome is promising as an adjuvant for the prevention/treatment of COVID-19 patients, due to immunomodulation properties related to probiotics and prebiotics. So far, few clinical studies involving the application of probiotics in COVID-19 patients have been completed, but reduction in the duration of the disease and the severity of symptoms as fatigue, olfactory dysfunction and breathlessness, nausea and vomiting and other gastrointestinal symptoms were some of the main findings. However, probiotics are not recommended to immunocompromised patients in corticosteroid therapy. The future perspectives point to the modulation of the intestinal microbiota by probiotics, prebiotics, synbiotics, and postbiotics represent a promising adjuvant approach for improving the health of patients with COVID-19.
冠状病毒病-19（COVID-19）是一种由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的传染病，该病毒有多种临床表现，包括胃肠道症状。
本综述旨在为使用益生菌、益生元、合生元和后生元作为辅助手段预防/治疗和/或调节COVID-19患者的微生物群提供见解和观点。对Scopus数据库中从疫情开始到2021年12月发表的84项研究进行了评估，并提交给了一种改编自VOSviewer软件的文献计量分析。
通过文献计量分析，由于益生菌和益生元具有免疫调节特性，肠道/肺部微生物群的调节作为预防/治疗COVID-19患者的辅助手段可能很有前景。到目前为止，很少有涉及在COVID-19患者中应用益生菌的临床研究完成，但疾病持续时间缩短以及疲劳、嗅觉功能障碍、呼吸急促、恶心、呕吐和其他胃肠道症状等症状严重程度降低是一些主要发现。然而，不建议在接受皮质类固醇治疗的免疫功能低下患者中使用益生菌。未来的研究方向表明，通过益生菌、益生元、合生元和后生元调节肠道微生物群是改善COVID-19患者健康的一种有前景的辅助方法。
